We're looking at Peter Marx. He was recently in a closed-door session. He's the head of the FDA at this point.

He's the acting director. He was in a closed-door session with Representative Jim Clyburn.

Jim Clyburn's the chairman of the select subcommittee on the coronavirus crisis. That's the official title of this.

And Representative Clyburn issued a statement after that briefing with Peter Marx.

And he had these quotes to say in here. Here's the actual briefing document.

And he said this. FDA will not withhold authorization based exclusively on vaccine efficacy at preventing symptomatic infection.

He says Dr. Marx explained that FDA would not withhold authorization for a pediatric vaccine solely because it did not reach

a 50% efficacy threshold at blocking symptomatic infection.

A requirement that had been previously listed in FDA guidance. So we're skipping that apparently.

He goes on to say Dr. Marx confirmed quote,

if these vaccines seem to be mirroring efficacy in adults and just seem to be less effective against Omicron,

like they are for adults, we will probably still authorize.

And these are extremely sweeping statements. You got to wonder if they did this behind closed doors because those sound bites

would be really damning at this point.

And good. I mean, because everyone's looking at it. Everyone is catching Omicron. Even Tony Fauci said,

the vaccine is absolutely useless. So I mean, here you have where you're ignoring the known side effects.

You're having to make ads for all the kids that are dropping over on the soccer field,

you know, clutching their chests. And while you're putting them at that risk, we don't even care if the thing is

totally ineffective, we're going to still approve it for them and recommend it to them.

And let's look. Is this a risk category? These kids are they at high risk? Now we've covered this before,

but if they're going to keep pushing it like this, we have to keep pushing back with with the data here.

So let's look at the CDC's own MMWR report. This is like their in-house science journal. This is

...